Possible interaction of anti-PD-1 Therapy with the effects of radiosurgery on brain metastases

Cancer Immunology Research

Volumn 4, Issue 6, 2016, Pages 481-487

  Alomari, Ahmed K ^a   Cohen, Justine ^a   Ovortmeyer, Alexander ^a   Chiang, Anne ^a   Gettinger, Scott ^a   Goldberg, Sarah ^a   Kluger, Harriet M ^a   Chiang, Veronica L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; DABRAFENIB; GADOLINIUM; IPILIMUMAB; LEVETIRACETAM; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PROGRAMMED DEATH 1; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; ASTROCYTOSIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURGERY; CASE REPORT; CONTROLLED STUDY; CRANIOTOMY; DISEASE COURSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LYMPH NODE BIOPSY; LYMPHOCYTIC INFILTRATION; MEDIASTINOSCOPY; MEDICAL HISTORY; MELANOMA; MIDDLE AGED; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE DISTRIBUTION; SEIZURE; STEREOTACTIC RADIOSURGERY; SYSTEMIC THERAPY; TREATMENT RESPONSE; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; DIAGNOSTIC IMAGING; GLIOSIS; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; RADIATION INJURIES; RADIOSURGERY; SECONDARY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; GLIOSIS; HUMANS; IMMUNOTHERAPY; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; RADIATION INJURIES; RADIOSURGERY;

EID: 84976602020     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0238     Document Type: Article

References (33)

1. Huber PE, Hawighorst H, Fuss M, van Kaick G, Wannenmacher MF, Debus J. Transient enlargement of contrast uptake on MRI after linear accelerator (linac) stereotactic radiosurgery for brain metastases. Int J Rad O B Phys 2001;49:1339-49.
2. Rauch PJ, Park HS, Knisely JP, Chiang VL, Vortmeyer AO. Delayed radiation- induced vasculitic leukoencephalopathy. Int J Radiat Oncol Biol Phys 2012;83:369-75.
3. Patel TR, McHugh BJ, Bi WL, Minja FJ, Knisely JP, Chiang VL. A comprehensive reviewofMR imaging changes following radiosurgery to 500 brain metastases. AJNR Am J Neuroradiol 2011;32:1885-92.
4. Alomari A, Rauch PJ, Orsaria M, Minja FJ, Chiang VL, Vortmeyer AO. Radiologic and histologic consequences of radiosurgery for brain tumors. J Neuro-Oncol 2014;117:33-42.
5. Kohutek ZA, Yamada Y, Chan TA, Brennan CW, Tabar V, Gutin PH, et al. Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. J Neurooncol 2015;125: 149-56.
6. Ruzevick J, Kleinberg L, Rigamonti D. Imaging changes following stereotactic radiosurgery for metastatic intracranial tumors: differentiating pseudoprogression from tumor progression and its effect on clinical practice. Neurosurg Rev 2014;37:193-201; discussion 201.
7. Kenchappa RS, Tran N, Rao NG, Smalley KS, Gibney GT, Sondak VK, et al. Novel treatments formelanoma brain metastases. Cancer Control J Moffitt Cancer Center 2013;20:298-306.
8. Hurst R, White DE, Heiss J, Lee DS, Rosenberg SA, Schwartzentruber DJ. Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: Is craniotomy indicated? J Immunother 1999; 22:356-62.
9. Declerck S, Vansteenkiste J. Immunotherapy for lung cancer: ongoing clinical trials. Future Oncol 2014;10:91-105.
10. Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2013;2:899-906.
11. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery formelanomabrain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 2012;117:227-33.
12. Margolin K.Ipilimumab in a Phase II trial of melanoma patients with brain metastases. Oncoimmunology 2012;1:1197-9.
13. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol 2008;26:677-704.
14. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75.
15. Turcotte S, Rosenberg SA. Immunotherapy formetastatic solid cancers. Adv Surg 2011;45:341-60.
16. Menzies AM, Long GV. New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Thera Adv Med Oncol 2013;5:278-85.
17. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
18. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
19. Domingues D, Turner A, Silva MD, Marques DS, Mellidez JC, Wannesson L, et al. Immunotherapy and lung cancer: current developments and novel targeted therapies. Immunotherapy 2014;6:1221-35.
20. Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, et al. Stereotactic radiosurgery formelanoma brainmetastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 2015;92:368-75.
21. Mathew M, Tam M, Ott PA, Pavlick AC, Rush SC, Donahue BR, et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 2013;23:191-5.
22. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA 2006;295:2483-91.
23. Mintz A, Perry J, Spithoff K, Chambers A, Laperriere N. Management of single brain metastasis: A practice guideline. Curr Oncol 2007;14: 131-43.
24. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): A novel strategy for the treatment of melanoma and other malignancies. Cancer 2007;110:2614-27.
25. Teply BA, Lipson EJ. Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology 2014;28 Suppl 3:30-8.
26. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: A revived partnership. Int J Rad Oncol Biol Phys 2005;63:655-66.
27. Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Rad Oncol Biol Phys 2012;84:879-80.
28. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170:6338-47.
29. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54-61.
30. Okwan-Duodu D, Pollack BP, Lawson D, Khan MK. Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J Clin Oncol 2015;38:119-25.
31. Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Rad Oncol Biol Phys 2013;85:293-5.
32. Kureshi SA, Hofman FM, Schneider JH, Chin LS, Apuzzo ML, Hinton DR. Cytokine expression in radiation-induced delayed cerebral injury. Neurosurgery 1994;35:822-9; discussion 9-30.
33. Moore AH, Olschowka JA, Williams JP, Paige SL, O'Banion MK. Radiationinduced edema is dependent on cyclooxygenase 2 activity in mouse brain. Rad Res 2004;161:153-60.